How The Delta Covid Variant Is Affecting Phoenix

Healthcare shortages create an increasingly worrying situation around the Delta Covid variant in Phoenix. The highly contagious Delta variant of Covid-19 is causing staffing shortages and pushing local hospitals beyond capacity. After a $60 million initiative to bolster staffing at healthcare centers treating coronavirus, members of the Phoenix community hope for improvement.

$60 million towards healthcare staffing

In light of ongoing healthcare staff shortages, where nursing staff has been hit the hardest, Gov. Doug Ducey has earmarked $60,000,000 to bolster staffing at hospitals administering monoclonal antibody therapy to treat Covid-19 patients.

Hopes are high for a reversal of current employment trends after the initiative goes into action. Valleywise Health, one of three major healthcare providers in the Phoenix metro, currently reports 400 open jobs. Almost half of those unfilled positions were for bedside nurses.

Monoclonal antibody treatment gaining popularity

Specifically targeted for expansion in this initiative was Phoenix’s availability of monoclonal antibody treatment (mAb). Monoclonal antibody treatment has been highlighted as a promising tool to reduce viral loads, lessen symptoms of Covid-19, and reduce or prevent hospitalizations.

When administered early, it decreases high-risk individuals’ likelihood to develop severe symptoms. This treatment is designed to reduce the  total amount of the coronavirus virus in the body.

Monoclonal Antibody Treatment In Phoenix – At Home

Due to the overcrowding and lack of staff at hospitals and healthcare clinics around the state, concerned citizens are turning to outside help for mAb treatment. Drip Hydration has launched at-home mAb treatment and Covid-19 testing to expand access during this healthcare crunch.

Administered by licensed clinicians, all of our coronavirus services provide a secure way to receive treatment from the comfort of your own home. Book now for your standard or rapid Covid test or to begin monoclonal antibody treatment.